Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Toi, M.
Right arrow Articles by Tominaga, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Toi, M.
Right arrow Articles by Tominaga, T.

Clinical Cancer Research, Vol 4, Issue 3 659-664, Copyright © 1998 by American Association for Cancer Research


ARTICLES

Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer

M Toi, T Taniguchi, T Ueno, M Asano, N Funata, K Sekiguchi, H Iwanari and T Tominaga
Department of Surgery, Tokyo Metropolitan Komagome Hospital, Japan.

The circulating hepatocyte growth factor (HGF)/scatter factor level is frequently increased in advanced cancer patients. In this study, we have assessed the prognostic value of the circulating HGF level determined by enzymatic immunoassay in primary breast cancer patients. Of 200 primary breast cancer patients, 54 (27.0%) showed the increase of serum HGF level according to the age-matched cutoff values. The prognosis of the patients with the increased HGF level was statistically worse than that of the patients with normal HGF level (P = 0.0001, log-rank test). Multivariate analysis confirmed that the increase in HGF level was an independent prognostic indicator in primary breast cancer patients. In the background analysis, the increase in serum HGF level was significantly associated with tumor size, nodal status, and histological evidence of venous invasion. The data indicate that up-regulation of the circulating HGF level may predict systemic tumor spread and early relapse in primary breast cancer patients.


This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
L. Vona-Davis and D. P Rose
Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression
Endocr. Relat. Cancer, June 1, 2007; 14(2): 189 - 206.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. D. Francone, R. G. Landmann, C.-T. Chen, M. Y. Sun, E. J. Kuntz, Z. Zeng, R. P. Dematteo, P. B. Paty, and M. R. Weiser
Novel xenograft model expressing human hepatocyte growth factor shows ligand-dependent growth of c-Met-expressing tumors
Mol. Cancer Ther., April 1, 2007; 6(4): 1460 - 1466.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Ohnishi, K. Kakimoto, K. Bandow, C. J. Lowenstein, Y. Daikuhara, and T. Matsuguchi
Mature Hepatocyte Growth Factor/Scatter Factor on the Surface of Human Granulocytes Is Released by a Mechanism Involving Activated Factor Xa.
J. Immunol., June 1, 2006; 176(11): 6945 - 6953.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
W. G. Jiang, A. Raz, A. Douglas-Jones, and R. E. Mansel
Expression of Autocrine Motility Factor (AMF) and Its Receptor, AMFR, in Human Breast Cancer
J. Histochem. Cytochem., February 1, 2006; 54(2): 231 - 241.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. G. Wright, J. Tsai, Z. Jia, and B. E. Elliott
Inhibition by Copper(II) Binding of Hepatocyte Growth Factor (HGF) Interaction with Its Receptor Met and Blockade of HGF/Met Function
J. Biol. Chem., July 30, 2004; 279(31): 32499 - 32506.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Parr, G. Watkins, R. E. Mansel, and W. G. Jiang
The Hepatocyte Growth Factor Regulatory Factors in Human Breast Cancer
Clin. Cancer Res., January 1, 2004; 10(1): 202 - 211.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
W. G. Jiang, D. Grimshaw, T. A. Martin, G. Davies, C. Parr, G. Watkins, J. Lane, R. Abounader, J. Laterra, and R. E. Mansel
Reduction of Stromal Fibroblast-induced Mammary Tumor Growth, by Retroviral Ribozyme Transgenes to Hepatocyte Growth Factor/Scatter Factor and its Receptor, c-MET
Clin. Cancer Res., September 15, 2003; 9(11): 4274 - 4281.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
R. E. Favoni and A. De Cupis
The Role of Polypeptide Growth Factors in Human Carcinomas: New Targets for a Novel Pharmacological Approach
Pharmacol. Rev., June 1, 2000; 52(2): 179 - 206.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W. Hung and B. Elliott
Co-operative Effect of c-Src Tyrosine Kinase and Stat3 in Activation of Hepatocyte Growth Factor Expression in Mammary Carcinoma Cells
J. Biol. Chem., April 6, 2001; 276(15): 12395 - 12403.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1998 by the American Association for Cancer Research.